Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 26

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 26
---
 sales will depend heavily on our ability to:

| ● | complete research and preclinical and clinical development of MEAI and any future product candidates in a timely and successful manner, including MEAI for the treatment of depression and addiction; |
| ● | obtain regulatory and marketing approval for any product candidates for which we complete clinical trials;                                                                                            |
| ● | maintain and enhance a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for MEAI and any future product candidates that is compliant with cGMPs;       |

| ● | establish and maintain supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support pre-clinical and future clinical development and the market demand for MEAI and any future product candidates, if and when approved; |
| ● | launch and commercialize any product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution infrastructure, and/or with collaborators or distributors;                                                                      |

17

| ● | expose and educate physicians and other medical professionals to use our products;                                                                                                        |
| ● | obtain market acceptance, if and when approved, of MEAI and any future product candidates from the medical community and third-party payors;                                              |
| ● | ensure our product candidates are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing; |
| ● | address any competing technological and market developments that impact MEAI and any future product candidates or their prospective usage by medical professionals;                       |
| ● | identify, assess, acquire and/or develop new product candidates;                                                                                                                          |
| ● | negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations;                            |
| ● | maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how;                                           |
| ● | avoid and defend against third-party interference or infringement claims;                                                                                                                 |
| ● | attract, hire and retain qualified personnel; and                                                                                                                                         |
| ● | locate and lease or acquire suitable facilities to support our pre-clinical and future clinical development, manufacturing facilities and commercial expansion.                           |

Even if MEAI or any future product candidates are approved for marketing and sale, we anticipate incurring significant incremental costs associated with commercializing such product candidates. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or EMA